Inflammation as a therapeutic target in myocardial infarction: Learning from past failures to meet future challenges

Amit Saxena, Ilaria Russo, Nikolaos G. Frangogiannis

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

In the infarcted myocardium, necrotic cardiomyocytes release danger signals, activating an intense inflammatory response. Inflammatory pathways play a crucial role in regulation of a wide range of cellular processes involved in injury, repair, and remodeling of the infarcted heart. Proinflammatory cytokines, such as tumor necrosis factor α and interleukin 1, are markedly upregulated in the infarcted myocardium and promote adhesive interactions between endothelial cells and leukocytes by stimulating chemokine and adhesion molecule expression. Distinct pairs of chemokines and chemokine receptors are implicated in recruitment of various leukocyte subpopulations in the infarcted myocardium. For more than the past 30 years, extensive experimental work has explored the role of inflammatory signals and the contributions of leukocyte subpopulations in myocardial infarction. Robust evidence derived from experimental models of myocardial infarction has identified inflammatory targets that may attenuate cardiomyocyte injury or protect from adverse remodeling. Unfortunately, attempts to translate the promising experimental findings to clinical therapy have failed. This review article discusses the biology of the inflammatory response after myocardial infarction, attempts to identify the causes for the translational failures of the past, and proposes promising new therapeutic directions. Because of their potential involvement in injurious, reparative, and regenerative responses, inflammatory cells may hold the key for design of new therapies in myocardial infarction.

Original languageEnglish (US)
Pages (from-to)152-166
Number of pages15
JournalTranslational Research
Volume167
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Chemokines
Myocardial Infarction
Learning
Inflammation
Myocardium
Leukocytes
Chemokine Receptors
Endothelial cells
Interleukin-1
Cardiac Myocytes
Adhesives
Repair
Adhesion
Tumor Necrosis Factor-alpha
Cytokines
Molecules
Wounds and Injuries
Therapeutics
Theoretical Models
Endothelial Cells

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, medical
  • Public Health, Environmental and Occupational Health

Cite this

Inflammation as a therapeutic target in myocardial infarction : Learning from past failures to meet future challenges. / Saxena, Amit; Russo, Ilaria; Frangogiannis, Nikolaos G.

In: Translational Research, Vol. 167, No. 1, 01.01.2016, p. 152-166.

Research output: Contribution to journalArticle

@article{f9379de4b676473986b6885157f7c037,
title = "Inflammation as a therapeutic target in myocardial infarction: Learning from past failures to meet future challenges",
abstract = "In the infarcted myocardium, necrotic cardiomyocytes release danger signals, activating an intense inflammatory response. Inflammatory pathways play a crucial role in regulation of a wide range of cellular processes involved in injury, repair, and remodeling of the infarcted heart. Proinflammatory cytokines, such as tumor necrosis factor α and interleukin 1, are markedly upregulated in the infarcted myocardium and promote adhesive interactions between endothelial cells and leukocytes by stimulating chemokine and adhesion molecule expression. Distinct pairs of chemokines and chemokine receptors are implicated in recruitment of various leukocyte subpopulations in the infarcted myocardium. For more than the past 30 years, extensive experimental work has explored the role of inflammatory signals and the contributions of leukocyte subpopulations in myocardial infarction. Robust evidence derived from experimental models of myocardial infarction has identified inflammatory targets that may attenuate cardiomyocyte injury or protect from adverse remodeling. Unfortunately, attempts to translate the promising experimental findings to clinical therapy have failed. This review article discusses the biology of the inflammatory response after myocardial infarction, attempts to identify the causes for the translational failures of the past, and proposes promising new therapeutic directions. Because of their potential involvement in injurious, reparative, and regenerative responses, inflammatory cells may hold the key for design of new therapies in myocardial infarction.",
author = "Amit Saxena and Ilaria Russo and Frangogiannis, {Nikolaos G.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.trsl.2015.07.002",
language = "English (US)",
volume = "167",
pages = "152--166",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Inflammation as a therapeutic target in myocardial infarction

T2 - Learning from past failures to meet future challenges

AU - Saxena, Amit

AU - Russo, Ilaria

AU - Frangogiannis, Nikolaos G.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - In the infarcted myocardium, necrotic cardiomyocytes release danger signals, activating an intense inflammatory response. Inflammatory pathways play a crucial role in regulation of a wide range of cellular processes involved in injury, repair, and remodeling of the infarcted heart. Proinflammatory cytokines, such as tumor necrosis factor α and interleukin 1, are markedly upregulated in the infarcted myocardium and promote adhesive interactions between endothelial cells and leukocytes by stimulating chemokine and adhesion molecule expression. Distinct pairs of chemokines and chemokine receptors are implicated in recruitment of various leukocyte subpopulations in the infarcted myocardium. For more than the past 30 years, extensive experimental work has explored the role of inflammatory signals and the contributions of leukocyte subpopulations in myocardial infarction. Robust evidence derived from experimental models of myocardial infarction has identified inflammatory targets that may attenuate cardiomyocyte injury or protect from adverse remodeling. Unfortunately, attempts to translate the promising experimental findings to clinical therapy have failed. This review article discusses the biology of the inflammatory response after myocardial infarction, attempts to identify the causes for the translational failures of the past, and proposes promising new therapeutic directions. Because of their potential involvement in injurious, reparative, and regenerative responses, inflammatory cells may hold the key for design of new therapies in myocardial infarction.

AB - In the infarcted myocardium, necrotic cardiomyocytes release danger signals, activating an intense inflammatory response. Inflammatory pathways play a crucial role in regulation of a wide range of cellular processes involved in injury, repair, and remodeling of the infarcted heart. Proinflammatory cytokines, such as tumor necrosis factor α and interleukin 1, are markedly upregulated in the infarcted myocardium and promote adhesive interactions between endothelial cells and leukocytes by stimulating chemokine and adhesion molecule expression. Distinct pairs of chemokines and chemokine receptors are implicated in recruitment of various leukocyte subpopulations in the infarcted myocardium. For more than the past 30 years, extensive experimental work has explored the role of inflammatory signals and the contributions of leukocyte subpopulations in myocardial infarction. Robust evidence derived from experimental models of myocardial infarction has identified inflammatory targets that may attenuate cardiomyocyte injury or protect from adverse remodeling. Unfortunately, attempts to translate the promising experimental findings to clinical therapy have failed. This review article discusses the biology of the inflammatory response after myocardial infarction, attempts to identify the causes for the translational failures of the past, and proposes promising new therapeutic directions. Because of their potential involvement in injurious, reparative, and regenerative responses, inflammatory cells may hold the key for design of new therapies in myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=84952639700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952639700&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2015.07.002

DO - 10.1016/j.trsl.2015.07.002

M3 - Article

C2 - 26241027

AN - SCOPUS:84952639700

VL - 167

SP - 152

EP - 166

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 1

ER -